[The effect of guanfacine on the background and nociceptive stimulation-induced activity of spinal cord neurons in rats].
Guanfacine in analgesic doses of 2.0 and 4.0 mg/kg inhibits the background activity of the spinal cord posterior horn neurons and their responses to nociceptive stimulation of the receptive field in conscious rats. Naloxone (0.1 mg/kg) does not change, whereas prazosin and yohimbine (both on doses of 0.1 mg/kg) remove and partly relieve the depressant effect of guanfacine.
Ivanov
V E
VE
D000284:Administration, Oral; D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000633:toxicity*; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000700:Analgesics / Q000008:administration & dosage / Q000633:toxicity*; D000818:Animals; D003863:Depression / Q000139:chemically induced / Q000188:drug therapy; D016316:Guanfacine / Q000008:administration & dosage / Q000633:toxicity*; D008297:Male; D009046:Motor Neurons / Q000166:cytology / Q000187:drug effects*; D009270:Naloxone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D011224:Prazosin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D013116:Spinal Cord / Q000166:cytology / Q000187:drug effects*; D013565:Sympatholytics / Q000008:administration & dosage / Q000633:toxicity*; D015016:Yohimbine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D000700:Analgesics; D009292:Narcotic Antagonists; D013565:Sympatholytics; D015016:Yohimbine; D016316:Guanfacine; D009270:Naloxone; D011224:Prazosin